Zusammenfassung
Ziel: Ziel der Studie war es, zu prüfen, ob es eine Korrelation zwischen dem histologischen Differenzierungsgrad und der Größe eines hepatozellulären Karzinoms einerseits und der SonoVue-Aufnahme im HCC andererseits gibt. Material und Methoden: In einer prospektiven Studie wurden 130 Patienten (72 Männer, 58 Frauen, 62 ± 10 Jahre) mit HCC untersucht, bei denen das HCC im sonografischen B-Bild nachweisbar war. Nach Injektion von 1,2 – 2,4 ml SonoVue i. v., wurde die Kontrastmittelaufnahme in der HCC-Raumforderung kontinuierlich bis zu 5 min in „low MI”-Technik untersucht. Ergebnisse: Bei Analyse der Gesamtgruppe war bei 72 % der HCC-Herde eine frühe arterielle Hypervaskularisation nachweisbar ohne Korrelation zur Größe oder zum histologischen Differenzierungsgrad. Bei der Analyse der G 1-Subgruppe fand sich hingegen eine signifikante Korrelation zwischen Durchmesser des HCC und der arteriellen Hypervaskularisation: Während bei 95 % der G 1-HCC’s > 3 cm eine arterielle Hypervaskularisation nachweisbar war, war bei den G 1-HCC’s < 3 cm eine Hypervaskularisation nur bei 43 % der Fälle nachweisbar (p < 0,001). Im Gegensatz dazu war bei den histologisch geringer differenzierten HCC’s (alle außer G 1) eine arterielle Hypervaskularisation bei 69 % der HCC’s < 3 cm und bei 72 % der HCC’s > 3 cm nachweisbar. In der Spätphase war in der G 1-Subgruppe eine echoarme Kontrastmittelaussparung bei 95 % der G 1-HCC’s > 3 cm, aber nur bei 64 % der G 1-HCC’s < 3 cm (p < 0,001). Im Gegensatz dazu fand sich bei den weniger differenzierten HCC-Herden (ohne G 1) eine Kontrastmittelaussparung bei 91 % (HCC > 3 cm) und in 82 % (HCC < 3 cm) der Fälle ohne Korrelation zur HCC-Größe. Schlussfolgerung: In gut differenzierten HCC’s (G1) korrelieren sowohl die arterielle Hypervaskularisation als auch die Kontrastmittelaussparung in der Spätphase mit dem HCC-Durchmesser.
Abstract
Purpose: The aim of the study was to characterize SonoVue enhancement in hepatocellular carcinoma in correlation to both lesion diameter and histological differentiation of the lesion. Materials and Methods: In a prospective study 130 patients (72 male, 58 female, 62 ± 10 years) with HCC lesions detected by B-mode sonography were examined. After injection of 1.2 – 2.4 ml SonoVue, HCC lesions were examined continuously for up to 5 min using ”low MI” sonography. Results: Arterial hypervascularization was found in 72 % of the HCC lesions without correlation to the lesion diameter or histological grading, when analyzed for the total group. However, the analysis of the G 1 subgroup showed significant correlation between lesion diameter and arterial hypervascularization. Arterial hypervascularization was found in 95 % of the G 1 lesions > 3 cm but in only 43 % of the G 1 lesions < 3 cm (p < 0.001). In contrast, analysis of the remaining HCC lesions (without G 1) showed arterial hypervascularization in 69 % of the lesions < 3 cm and in 72 % of the lesions > 3 cm (n. s.) without correlation to the diameter. In the late phase in the G 1 subgroup, hypoechoic demarcation was found in 95 % of the G 1 lesions > 3 cm, but in only 64 % of the G 1 lesions < 3 cm (p < 0.001). In contrast, in the less differentiated HCC lesions (without G 1), hypoechoic demarcation was found in 91 % (HCC > 3 cm) and in 82 % (HCC < 3 cm) of the lesions (n. s.). Conclusion: In well-differentiated HCCs (G1) hyperechoic enhancement in the arterial phase and hypoechoic demarcation in the late phase correlate to the diameter.
Key words
abdomen - contrast agents - ultrasound
References
1
Qauia E, Degobbis F, Tona G. et al .
Differential patterns of contrast enhancement in different focal liver lesions after injection of the microbubble US contrast agent SonoVue.
Radiol Med.
2004;
107
155-165
2
Jang H J, Kim T K, Burns P N. et al .
Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: Comparison with histologic differentiation.
Radiology.
2007;
244
898-906
3
Herbay von A, Vogt C, Willers R. et al .
Real-time imaging with the sonographic contrast agent SonoVue: Differentiation between benign and malignant hepatic lesions.
J Ultrasound Med.
2004;
23
1557-1568
4
Strobel, Seitz K, Blank W.
Contrast-enhanced ultrasound for the characterization of focal liver lesions – diagnostic accuracy in clinical practice (DEGUM multicenter trial).
Ultraschall in Med.
2008;
29
499-505
5
Strobel D, Kleinecke C, Hansler J. et al .
Contrast-enhanced sonography for the characterisation of hepatiocellular carcinomas-correlation with histological differentiation.
Ultraschall in Med.
2005;
26
270-276
6
Ding H D, Wang W P, Huang B J.
Imaging of focal liver lesions: low mechanical-index real-time ultrasonography with SonoVue.
J Ultrasound Med.
2005;
24
285-297
7
Herbay von A, Vogt C, Häussinger D.
Late-phase pulse-inversion sonography using the contrast agent Levovist: differentiation between benign and malignant focal lesions of the liver.
Am J Roentgenol.
2002;
179
1273-1279
8
Herbay von A, Vogt C, Häussinger D.
Pulse-inversion-sonography in the early phase of the ultrasound contrast agent Levovist: differentiation between benign and malignant focal liver lesions.
J Ultrasound Med.
2002;
21
1191-1200
9
Herbay von A, Vogt C, Häussinger D.
Differentiation between benign and malignant hepatic lesions: utility of color stimulated acoustic emission with the microbubble contrast agent Levovist.
J Ultrasound Med.
2004;
23
207-215
10
Albrecht T, Hoffmann C W, Schettler S A. et al .
Phase-inversion sonography during the liver-specific late phase of contrast-enhancement: improved detection of liver metastases.
Am J Roentgenol.
2001;
176
1191-1198
11
Dörffel Y, Wermke W.
Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography.
Ultraschall in Med.
2008;
29
506-514
12
Herbay von A, Häussinger D, Gregor M. et al .
Characterization and detection of hepatocellular carcinoma (HCC): comparison of the ultrasound contrast agents SonoVue (BR 1) and levovist (SH U 508 A) – comparison of SonoVue and Levovist in HCC.
Ultraschall in Med.
2007;
28
168-175
13
Dietrich C F, Ignee A, Trojan J. et al .
Improved characterisation of histologically proven liver tumors by contrast enhanced ultrasonography during the portal venous and specific late phase of SH U 508 A.
Gut.
2004;
53
401-405
14
Herbay von A, Donner A, Jung G. et al .
Contrast-enhanced-sonography of the liver is important for planning of the therapeutical strategy in hepatocellular carcinoma.
Med Klin.
2004;
99
89-92
15
Nicolau C, Catalá V, Vilana R. et al .
Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation.
Eur Radiol.
2004;
14
1092-1099
16
Torzilli G, Olivari N, Moroni E. et al .
Contrast-enhanced intraoperative ultrasonography in surgery for hepatocellular carcinoma in cirrhosis.
Liver Transplantation.
2004;
10 (2 Suppl 1)
S34-S38
17
Solbiati L, Tonollini M, Cova L. et al .
The role of contrast-enhanced ultrasound in the detection of focal liver lesions.
Eur Radiol.
2001;
11
E15-E26
18
Numata K, Tanaka K, Kiba T. et al .
Contrast-enhanced, wide-band harmonic gray-scale imaging of hepatocellular carcinoma.
J Ultrasound Med.
2001;
20
89-98
19
Rickes S, Schulze S, Neye H. et al .
Improved diagnosing of small carcinomas by echo-enhanced power Doppler sonography in patients with cirrhosis.
Eur J Gastroenterol & Hepatol.
2003;
15
881-883
20
Honda H, Tajima T, Tagucji K. et al .
Recent developments in imaging diagnostics for HCC: CT arteriography and CT arterioportography evaluation of vascular changes in premalignant hepatic nodules.
J Hepatobiliary Pancreat Surg.
2000;
7
245-251
21
Amano S, Ebara M, Yajima T. et al .
Assessment of cancer cell differentiation in small hepatocellular carcinoma by computed tomography and magnetic resonance imaging.
J Gastroenterol Hepatol.
2003;
18
273-279
22
Noguchi Y, Murakami T, Kim T. et al .
Detection of hepatocellular carcinoma: comparison of dynamic MR-imaging with dynamic double arterial phase helical CT.
Am J Roentgenol.
2003;
180
455-460
23
Zhou L, Rui J A, Ye D X. et al .
Edmondson-Steiner grading increases the predictive efficiency of TNM staging für long-term survival of patients with hepatocellular carcinoma after curative resection.
World J Surrg.
2008;
32
1748-1756
24 Hirohashi S, Ishak K G, Kojiro M. et al .Hepatocellular carcinoma. Hamilton SR, Aaltonen LA World health classification of tumours. Pathology and genetics of tumours of the digestive system Lyon; IARC 159-172
25
Edmondson H A, Steiner P E.
Primary carcinoma of the liver. A study of 100 cases among 48 900 autopsies.
Cancer.
1954;
7
462-503
26
Konopke R, Kersting S, Saeger H D. et al .
Detection of liver lesions by contrast-enhanced ultrasound-comparison to intraoperative findings.
Ultraschall in Med.
2005;
26
107-113
27
Fan Z H, Chen M H, Dai Y.
Evaluation of primary malignancies of the liver using contrast-enhanced sonography: correlation with pathology.
Am J Roentgenol.
2006;
186
1512-1519
28
Cosgrove D, Blomley M.
Liver tumors: evaluation with contrast-enhanced ultrasound.
Abdom Imaging.
2004;
29
446-454
29
Dietrich C F.
Characterisation of focal liver lesions with contrast enhanced ultrasonography.
Eur J Radiol.
2004;
51
S9-S17
30
Honda H, Tajima T, Kajiyama K. et al .
Vascular changes in hepatocellular carcinoma: correlation of radiologic and pathologic findings.
Am J Roentgenol.
1999;
173
1213-1217
31
Craig J R, Peters R L, Edmondson H A. et al .
Fibrolamellar carcinoma of the liver: a tumor of adolescents and clinico-pathologic features.
Cancer.
1980;
46
372-379
Prof. Dr. Alexandra von Herbay
Internal Medicine, University of Tuebingen
Otfried-Müller-Straße 10
72076 Tübingen
Telefon: ++ 49/70 71/2 98 27 11
Fax: ++ 49/70 71/29 45 38
eMail: Alexandra.vonHerbay@med.uni-tuebingen.de